Frontotemporal degeneration

What might a family notice first?

Changes in behavior or judgment

A person may become less motivated, less considerate of social boundaries, or more rigid in routines. They may make decisions that feel out of character, lose interest in people or activities, repeat the same action, or change how they eat.

These changes can be mistaken for depression, a relationship problem, a psychiatric illness, or intentional behavior. Sometimes the person has limited awareness that anything has changed. Concrete examples from family, friends, or coworkers may therefore be as important as the person's own report.

When behavior, judgment, or executive abilities are the first and clearest changes, clinicians may use the term behavioral-variant frontotemporal dementia, or bvFTD.

Changes in language or speech

For some people, the first difficulty is communicating. They may pause while searching for words, lose the meaning of familiar words, speak with increasing effort, or have trouble constructing a sentence.

The broad clinical term primary progressive aphasia, or PPA, describes a gradual decline in language caused by disease in the brain's language networks. There are several forms of PPA, and they do not all have the same underlying cause.

Aphasia affects language. It should not be mistaken for a loss of intelligence or a loss of personhood.

Changes in movement

FTD-related disorders can overlap with movement conditions. Early changes may include stiffness, slowness, falls, difficulty directing the eyes, trouble coordinating one limb, changes in speech or swallowing, or progressive muscle weakness.

Progressive supranuclear palsy, corticobasal syndrome, and FTD with motor neuron disease or ALS sit within this broader clinical neighborhood. A movement problem does not automatically mean FTD, but movement and cognitive symptoms should be considered together rather than divided into unrelated stories.

A clinical pattern is not the same as its biological cause

Terms such as bvFTD, PPA, progressive supranuclear palsy, and corticobasal syndrome describe recognizable patterns of symptoms. They tell us which brain functions appear to be changing. They do not always tell us which protein or disease process is responsible.

The pathology most closely associated with the FTD family is called frontotemporal lobar degeneration, or FTLD. The most common underlying protein changes involve tau or TDP-43. A smaller group involves a protein called FUS.

The relationship is not one-to-one. The same clinical syndrome can be caused by different proteins, and the same underlying protein can produce different symptoms in different people. Alzheimer's disease can also cause some language-led or movement-led syndromes, including many cases of logopenic PPA and some cases of corticobasal syndrome.

This is why a clinician may be confident about the syndrome before being equally certain about the underlying biology.

How is FTD evaluated?

There is no single routine blood test that confirms every form of FTD. The evaluation brings several kinds of information together:

• the first change and how it has progressed;
• examples from someone who knows the person well;
• neurological examination;
• testing of memory, language, executive function, social cognition, and movement;
• brain MRI and, in selected cases, FDG PET or other imaging;
• laboratory testing for other medical explanations;
• biomarkers that assess whether Alzheimer's disease is a more likely cause;
• genetic counseling and testing when appropriate.

MRI may reveal a pattern involving frontal or temporal regions, but an early scan can be subtle. FDG PET can sometimes show changes in how brain regions use energy before structural changes are obvious.

Blood or spinal fluid NfL may indicate that neurodegeneration is active, but it does not identify FTD as the cause. Alzheimer's biomarkers can be particularly useful when the symptoms could reflect either Alzheimer's disease or an FTD-related process.

What role does genetics play?

Most people with FTD do not have a known disease-causing genetic variant. However, genetic causes are more common in FTD than in typical later-life Alzheimer's disease.

The most frequently identified genes are C9orf72, GRN, and MAPT. Different relatives carrying the same genetic change may begin at different ages or develop different combinations of behavior, language, movement, or motor-neuron symptoms.

Genetic counseling can help determine whether testing is appropriate, whom to test first, and what a positive, negative, or uncertain result would mean for the individual and their relatives. When possible, testing usually begins with the family member who has symptoms.

What can help now?

Even when the biological cause is not fully resolved, the clinical pattern can guide useful care. The plan may include:

• speech and communication support;
• occupational or physical therapy;
• review of behavior, mood, sleep, movement, and swallowing symptoms;
• driving, financial, medication, and home-safety planning;
• support for the family member or friend coordinating care;
• genetic counseling or research participation when appropriate.

The goal is not only to name the condition. It is to understand which abilities are changing, protect the abilities that remain, and anticipate the kinds of support that may become useful.

Preparing for an evaluation

It helps to write down:

• what changed first;
• two or three specific examples;
• when the change began and whether it has progressed;
• changes at work, at home, in finances, or in social situations;
• any language, movement, sleep, or swallowing symptoms;
• neurological or psychiatric conditions in parents, siblings, children, grandparents, aunts, and uncles.

The first symptom is often more informative than the symptom that has become most obvious by the time of the appointment.